John Mohr
Technik-/Wissenschafts-/F&E-Leiter bei SCPHARMACEUTICALS INC.
Aktive Positionen von John Mohr
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SCPHARMACEUTICALS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2018 | - |
Karriereverlauf von John Mohr
Ehemalige bekannte Positionen von John Mohr
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2015 | 01.05.2016 |
| THE MEDICINES COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2015 | 01.06.2015 |
| The University of Texas Medical School At Houston | Corporate Officer/Principal | 01.01.2003 | 01.10.2007 |
Ausbildung von John Mohr
| Texas A&M University | Undergraduate Degree |
| University of Houston | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SCPHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
